A general metal-free route to 1,4-disubstituted and 1,4,5-trisubstituted 1,2,3-triazoles was developed. α-Haloacroleins reacted with organic azides in a DMSO/H2O mixture solvent at room temperature to produce 1,4-disubstituted triazoles (up to 99%) with exclusive regioselectivities. This protocol is convenient and scalable with a broad substrate scope including aliphatic and aromatic azides. The resulting
开发了一种通向1,4-二取代和1,4,5-三取代的1,2,3-三唑的无金属路线。在室温下,α-卤代丙烯醛与有机叠氮化物在DMSO / H 2 O混合溶剂中反应,生成具有区域选择性的1,4-二取代三唑(最高99%)。该协议方便且可扩展,具有广泛的底物范围,包括脂肪族和芳香族叠氮化物。所得三唑在C4位上显示醛基,并证明了其合成用途。还鉴定了一种含有非对映体质子的1,2,3-三唑化合物。
Catalytic Enantioselective [2+2] Cycloaddition of α‐Halo Acroleins: Construction of Cyclobutanes Containing Two Tetrasubstituted Stereocenters
A catalytic enantioselective formal [2+2] cycloaddition between α‐halo acroleins and electronically diverse arylalkenes is described. In the presence of (S)‐oxazaborolidinium cation as the catalyst, densely functionalized cyclobutanes containing two vicinal tetrasubstituted stereocenters were produced in high yields and high diastereoselectivities with excellent enantioselectivities. Mechanistic studies
Swapped selectivities: The use of tailor‐made catalysts results in anomalous endo/exo selectivities and high enantioselectivities in the Diels–Alder reactions of cyclopentadiene with different acroleins (see scheme). These supramolecular catalysts are prepared in situ from chiral diols, arylboronic acid, and tris(pentafluorophenyl)borane, and can discriminate the re/si face of the dienophile as well
BBr3-chiral phosphoric acid complexes are highly effective and practical Lewis acid-assisted Brønsted acid (LBA) catalysts for promoting the enantioselective Diels-Alder (DA) reaction of α-substituted acroleins and α-CF3 acrylate. In particular, the DA reaction of α-substituted acroleins with 1,2-dihydropyridines gave the corresponding optically active isoquinuclidines with high enantioselectivities
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.